Non-Hodgkin's Lymphoma

Millenium C41004

INDICATION:
Non-Hodgkin’s Lymphoma

TITLE:
A Phase 2 Trial of MLN8237, an Oral Aurora-A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin’s Lymphoma

IRB NAME:
Copernicus Group IRB

STATUS:
Closed to enrollment

PHASE:
2

PURPOSE:
To estimate the antitumor activity of MLN8237 measured by the response rate in patients with relapsed or refractory NHL

ELIGIBILITY:
Candidates must meet the following eligibility requirements:

• Be aged 18 years or older
• Patients must have a histologic or cytologic diagnosis of a hematologic malignancy of the following types that has relapsed or was refractory to prior therapy:
  • Diffuse large B-cell lymphoma
  • Mantle cell lymphoma
  • Burkitt’s lymphoma
  • Precursor B-lymphoblastic leukemia/lymphoma
  • T-cell lymphoma, excluding primary cutaneous T-cell lymphoma
  • Transformed follicular lymphoma with ≥50% diffuse large cell component

DURATION:
15 visits over 30 months

CONTACT/ADDITIONAL INFO:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630